• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Available positions at Diamyd Medical

We welcome candidates with relevant experience to join our entrepreneurial and collaborative team.

 

Calendar

 Dates for financial information and other events
January 9 − January 12, 2023
BIO Partnering at JPM
January 9-12, 2023, San Francisco, CA
January 25, 2023
Quarterly Report I
Quarterly Report 1 2022/2023
February 27 − March 1, 2023
6th Antigen-Specific Immune Tolerance Summit
April 5, 2023
Quarterly Report II
Quarterly Report 2 2022/2023
June 28, 2023
Quarterly Report III
Quarterly Report 3 2022/2023
October 11, 2023
Year-end report
Year-end report 2022/2023

We are on the verge of radically changing how autoimmune diabetes should be treated. The antigen-specific immunotherapy Diamyd® targets individuals who carry a specific gene type found in up to 40% of all people who suffer from or are at risk of autoimmune diabetes, a textbook example of precision medicine. This is a great discovery and a paradigm shift in the field.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Annual Report 21/22

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

GAD PRODUCTS